journal article·2023-02-09Open access

Non-interfacial self-assembly of synthetic protocells

Xiaolin Xu, Wencai Guan, Xiaolei Yu, Guoxiong Xu, Chenglong Wang

Biomaterials Research· Volume 27· Issue 1

Abstract

Abstract Background Protocell refers to the basic unit of life and synthetic molecular assembly with cell structure and function. The protocells have great applications in the field of biomedical technology. Simulating the morphology and function of cells is the key to the preparation of protocells. However, some organic solvents used in the preparation process of protocells would damage the function of the bioactive substance. Perfluorocarbon, which has no toxic effect on bioactive substances, is an ideal solvent for protocell preparation. However, perfluorocarbon cannot be emulsified with water because of its inertia. Methods Spheroids can be formed in nature even without emulsification, since liquid can reshape the morphology of the solid phase through the scouring action, even if there is no stable interface between the two phases. Inspired by the formation of natural spheroids such as pebbles, we developed non-interfacial self-assembly (NISA) of microdroplets as a step toward synthetic protocells, in which the inert perfluorocarbon was utilized to reshape the hydrogel through the scouring action. Results The synthetic protocells were successfully obtained by using NISA-based protocell techniques, with the morphology very similar to native cells. Then we simulated the cell transcription process in the synthetic protocell and used the protocell as an mRNA carrier to transfect 293T cells. The results showed that protocells delivered mRNAs, and successfully expressed proteins in 293T cells. Further, we used the NISA method to fabricate an artificial cell by extracting and reassembling the membrane, proteins, and genomes of ovarian cancer cells. The results showed that the recombination of tumor cells was successfully achieved with similar morphology as tumor cells. In addition, the synthetic protocell prepared by the NISA method was used to reverse cancer chemoresistance by restoring cellular calcium homeostasis, which verified the application value of the synthetic protocell as a drug carrier. Conclusion This synthetic protocell fabricated by the NISA method simulates the occurrence and development process of primitive life, which has great potential application value in mRNA vaccine, cancer immunotherapy, and drug delivery. Graphical Abstract
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Origins and Evolution of Life · Supramolecular Self-Assembly in Materials · Photosynthetic Processes and Mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Research Center for Clinical Medicine, Jinshan Hospital, Fudan University, Shanghai 201508, P.R. China.

The State Key Laboratory of Metal Matrix Composites, School of Materials Science and Engineering, Shanghai Jiao Tong University, Shanghai 200240, P. R. China.

Funding

National Natural Science Foundation of China

References (50)

Show source-provided references
1. Ashley CE, Carnes EC, Phillips GK, et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat Mater. 2011;10(5):389–97. 1:CAS:528:DC%2BC3MXkvVKmuro%3D10.1038/nmat2992 ↗
2. 10.1039/C1CS15211D10.1039/C1CS15211D ↗
3. Ianeselli A, Tetiker D, Stein J, et al. Non-equilibrium conditions inside rock pores drive fission, maintenance and selection of coacervate protocells. Nat Chem. 2022;14(1):32–9. 1:CAS:528:DC%2BB3MXis1OrtbzJ10.1038/s41557-021-00830-y ↗
4. Xu C, Hu S, Chen X. Artificial cells: from basic science to applications. Mater Today (Kidlington). 2016;19(9):516–32. 1:CAS:528:DC%2BC28XjvFKit7c%3D10.1016/j.mattod.2016.02.020 ↗
5. 10.1021/acsnano.2c0610410.1021/acsnano.2c06104 ↗
6. Tian L, Li M, Patil AJ, Drinkwater BW, Mann S. Artificial morphogen-mediated differentiation in synthetic protocells. Nat Commun. 2019;10(1):3321.10.1038/s41467-019-11316-4 ↗
7. 10.1021/acsnano.0c0212710.1021/acsnano.0c02127 ↗
8. 10.1038/nature0701810.1038/nature07018 ↗
9. 10.1038/ncomms323910.1038/ncomms3239 ↗
10. Li M, Harbron RL, Weaver JVM, Binks BP, Mann S. Electrostatically gated membrane permeability in inorganic protocells. Nat Chem. 2013;5(6):529–36. 1:CAS:528:DC%2BC3sXntVaksrY%3D10.1038/nchem.1644 ↗
11. Liu SY, Zhang YW, Li M, et al. Enzyme-mediated nitric oxide production in vasoactive erythrocyte membrane-enclosed coacervate protocells. Nat Chem. 2020;12(12):1165–73. 1:CAS:528:DC%2BB3cXitl2qs7vK10.1038/s41557-020-00585-y ↗
12. Gao N, Li M, Tian LF, Patil AJ, Kumar B, Mann S. Chemical-mediated translocation in protocell-based microactuators. Nat Chem. 2021;13(9):868–79. 1:CAS:528:DC%2BB3MXhsVSmsb3L10.1038/s41557-021-00728-9 ↗
13. 10.1016/j.nantod.2019.10076610.1016/j.nantod.2019.100766 ↗
14. Ulmer JB, Geall AJ. Recent innovations in mRNA vaccines. Curr Opin Immunol. 2016;41:18–22. 1:CAS:528:DC%2BC28XosFWgur0%3D10.1016/j.coi.2016.05.008 ↗
15. 10.1517/17425247.2014.90130810.1517/17425247.2014.901308 ↗
16. 10.1038/nrd.2017.24310.1038/nrd.2017.243 ↗
17. 10.1177/205101361350872910.1177/2051013613508729 ↗
18. 10.1007/s12274-018-2095-810.1007/s12274-018-2095-8 ↗
19. 10.3389/fimmu.2019.0059410.3389/fimmu.2019.00594 ↗
20. 10.1016/j.ymthe.2019.01.02010.1016/j.ymthe.2019.01.020 ↗
21. Guevara ML, Persano S, Persano F. Lipid-based vectors for therapeutic mRNA-Based anti-cancer vaccines. Curr Pharm Des. 2019;25(13):1443–54. 1:CAS:528:DC%2BC1MXhslWrsrjL10.2174/1381612825666190619150221 ↗
22. 10.4161/rna.2226910.4161/rna.22269 ↗
23. 10.1016/bs.adgen.2014.10.00510.1016/bs.adgen.2014.10.005 ↗
24. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol. 2008;183:221–35. 1:CAS:528:DC%2BD1cXitlWqs7k%3D10.1007/978-3-540-72167-3_11 ↗
25. 10.1080/14760584.2017.135524510.1080/14760584.2017.1355245 ↗
26. 10.1126/science.aar671110.1126/science.aar6711 ↗
27. 10.1016/j.ebiom.2020.10297510.1016/j.ebiom.2020.102975 ↗
28. Moss P, Rickinson A. Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol. 2005;5(1):9–20. 1:CAS:528:DC%2BD2MXlvVOg10.1038/nri1526 ↗
29. De Gruijl TD, Van Den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57(10):1569–77. 1:CAS:528:DC%2BD1cXovFyisbs%3D10.1007/s00262-008-0536-z ↗
30. 10.4161/hv.2656810.4161/hv.26568 ↗
31. 10.1586/14760584.2014.96971410.1586/14760584.2014.969714 ↗
32. 10.1038/nchem.261710.1038/nchem.2617 ↗
33. 10.3390/pharmaceutics1107032710.3390/pharmaceutics11070327 ↗
34. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat Rev Cancer. 2018;18(7):452–64. 1:CAS:528:DC%2BC1cXosVCgt7Y%3D10.1038/s41568-018-0005-8 ↗
35. 10.1002/hon.287510.1002/hon.2875 ↗
36. Qian J Lesavage BL Hubka KM et al. Cancer-associated mesothelial cells promote ovarian cancer chemoresistance through paracrine osteopontin signaling. J Clin Invest 131(16) e146186 (2021).10.1172/JCI146186 ↗
37. Dora Tang TY, Rohaida Che Hak C, Thompson AJ, et al. Fatty acid membrane assembly on coacervate microdroplets as a step towards a hybrid protocell model. Nat Chem. 2014;6(6):527–33. 1:CAS:528:DC%2BC2cXmsVKmu7Y%3D10.1038/nchem.1921 ↗
38. Park K. Protocells for DNA cargo delivery to the spinal cord. J Control Release. 2013;168(2):238. 1:CAS:528:DC%2BC3sXotF2hsLk%3D10.1016/j.jconrel.2013.04.014 ↗
39. Krinsky N Kaduri M Zinger A et al. Synthetic cells synthesize therapeutic proteins inside tumors. Adv Healthc Mater 7(9) e1701163 (2018).10.1002/adhm.201701163 ↗
40. 10.1002/chem.20140034810.1002/chem.201400348 ↗
41. Liu J, Zhu C, Xu L, et al. Nanoenabled Intracellular Calcium bursting for safe and efficient reversal of Drug Resistance in Tumor cells. Nano lett. 2020;20(11):8102–11. 1:CAS:528:DC%2BB3cXitVOjs7rF10.1021/acs.nanolett.0c03042 ↗
42. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. 2017;390(10101):1511–20. 1:CAS:528:DC%2BC2sXht1Cjsr7N10.1016/S0140-6736(17)31665-3 ↗
43. 10.1016/j.jconrel.2015.08.00710.1016/j.jconrel.2015.08.007 ↗
44. Phua KKL, Staats HF, Leong KW, Nair SK. Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity. Sci Rep. 2014;4:5128. 1:CAS:528:DC%2BC2MXksVyns78%3D10.1038/srep05128 ↗
45. 10.1007/s12274-018-2091-z10.1007/s12274-018-2091-z ↗
46. 10.1038/nrd427810.1038/nrd4278 ↗
47. 10.1007/s12274-018-2146-110.1007/s12274-018-2146-1 ↗
48. Li B, Zhang X, Dong Y. Nanoscale platforms for messenger RNA delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11(2):e1530.10.1002/wnan.1530 ↗
49. Midoux P, Pichon C. Lipid-based mRNA vaccine delivery systems. Expert Rev Vaccines. 2015;14(2):221–34. 1:CAS:528:DC%2BC2MXnslehsA%3D%3D10.1586/14760584.2015.986104 ↗
50. 10.1039/C4NR01346H10.1039/C4NR01346H ↗